Skip to main content
Top
Published in: Breast Cancer Research 4/2001

Open Access 01-08-2001 | Research article

Possible association of β2- and β3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer

Authors: Xin-En Huang, Nobuyuki Hamajima, Toshiko Saito, Keitaro Matsuo, Mitsuhiro Mizutani, Hiroji Iwata, Takuji Iwase, Shigeto Miura, Tsutomu Mizuno, Shinkan Tokudome, Kazuo Tajima

Published in: Breast Cancer Research | Issue 4/2001

Login to get access

Abstract

Background

The involvement of β2-adrenergic receptor (ADRB2) and β3-adrenergic receptor (ADRB3) in both adipocyte lipolysis and thermogenic activity suggests that polymorphisms in the encoding genes might be linked with interindividual variation in obesity, an important risk factor for postmenopausal breast cancer. In order to examine the hypothesis that genetic variations in ADRB2 and ADRB3 represent interindividual susceptibility factors for obesity and breast cancer, we conducted a hospital-based, case-control study in the Aichi Cancer Center, Japan.

Methods

A self-administered questionnaire was given to 200 breast cancer patients and 182 control individuals, and pertinent information on lifestyle, family history and reproduction was collected. ADRB2 and ADRB3 genotypes were determined by polymerase chain reaction (PCR) restriction fragment length polymorphism assessment.

Results

Twenty-five (12.4%) breast cancer patients and 32 (17.6%) control individuals were found to bear a glutamic acid (Glu) allele for the ADRB2 gene (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.38-1.18), and 60 (30.0%) breast cancer patients and 61 (33.5%) control individuals were found to bear an Arg allele for the ADRB3 gene (OR 0.85, 95% CI 0.55-1.31). A significantly lower risk was observed in those who carried the Glu ADRB2 allele and who reported first childbirth when they were younger than 25 years (OR 0.35; 95% CI 0.13-0.99).

Conclusion

A potential association may exist between risk of breast cancer and polymorphisms in the ADRB2 and ADRB3 genes; further studies in larger samples and/or in different ethnic groups are warranted to investigate this potential association.
Literature
1.
go back to reference Parkin DM, Pisani P, Ferlay J: Estimates of the world incidence of 25 major cancers in 1990. Int J Cancer. 1999, 80: 827-841. 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P.PubMedCrossRef Parkin DM, Pisani P, Ferlay J: Estimates of the world incidence of 25 major cancers in 1990. Int J Cancer. 1999, 80: 827-841. 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P.PubMedCrossRef
2.
go back to reference Kuroishi T, Nishikawa Y, Tominaga S, Aoki K: Cancer mortality statistics in 33 countries (1953-1992). Gann Monogr Cancer Res. 1999, 47: 153-217. Kuroishi T, Nishikawa Y, Tominaga S, Aoki K: Cancer mortality statistics in 33 countries (1953-1992). Gann Monogr Cancer Res. 1999, 47: 153-217.
3.
go back to reference Hirose K, Tajima K, Hamajima N, Takezaki T, Inoue M, Kuroishi T, Miura S, Tokudome S: Effect of body size on breast-cancer risk among Japanese women. Int J Cancer. 1999, 80: 349-355. 10.1002/(SICI)1097-0215(19990129)80:3<349::AID-IJC3>3.0.CO;2-8.PubMedCrossRef Hirose K, Tajima K, Hamajima N, Takezaki T, Inoue M, Kuroishi T, Miura S, Tokudome S: Effect of body size on breast-cancer risk among Japanese women. Int J Cancer. 1999, 80: 349-355. 10.1002/(SICI)1097-0215(19990129)80:3<349::AID-IJC3>3.0.CO;2-8.PubMedCrossRef
4.
go back to reference Vatten LJ, Kvinnsland S: Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women. Int J Cancer. 1990, 45: 440-444.PubMedCrossRef Vatten LJ, Kvinnsland S: Body mass index and risk of breast cancer. A prospective study of 23,826 Norwegian women. Int J Cancer. 1990, 45: 440-444.PubMedCrossRef
5.
go back to reference Lafontan M, Berlan M: Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993, 34: 1057-1091.PubMed Lafontan M, Berlan M: Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993, 34: 1057-1091.PubMed
7.
go back to reference Emorine LJ, Marullo SM, Briend-Sutren M, Patey G, Tate K, Delavier-Klutchko C, Strosberg D: Molecular characterization of the human β3-adrenergic receptor. Science. 1989, 245: 1118-1121.PubMedCrossRef Emorine LJ, Marullo SM, Briend-Sutren M, Patey G, Tate K, Delavier-Klutchko C, Strosberg D: Molecular characterization of the human β3-adrenergic receptor. Science. 1989, 245: 1118-1121.PubMedCrossRef
8.
go back to reference Granneman JG, Lahners KN, Chaudry A: Characterization of the human β3-adrenergic receptor gene. Mol Pharmacol. 1993, 44: 264-270.PubMed Granneman JG, Lahners KN, Chaudry A: Characterization of the human β3-adrenergic receptor gene. Mol Pharmacol. 1993, 44: 264-270.PubMed
9.
go back to reference Lelias JM, Kaghad M, Rodriguez M, Chalon P, Bonnin J, Dupré I, Delpech B, Bensaid M, LeFur G, Ferrara P, Caput D: Molecular cloning of a human β3-adrenergic receptor. FEBS Lett. 1993, 324: 127-130. 10.1016/0014-5793(93)81377-C.PubMedCrossRef Lelias JM, Kaghad M, Rodriguez M, Chalon P, Bonnin J, Dupré I, Delpech B, Bensaid M, LeFur G, Ferrara P, Caput D: Molecular cloning of a human β3-adrenergic receptor. FEBS Lett. 1993, 324: 127-130. 10.1016/0014-5793(93)81377-C.PubMedCrossRef
10.
go back to reference Enocksson S, Shimizu M, Lonnqvist F, Nordenstrom J, Arner P: Demonstration of an in vivo functional β3-adrenoceptor in man. J Clin Invest. 1995, 95: 2239-2245.PubMedPubMedCentralCrossRef Enocksson S, Shimizu M, Lonnqvist F, Nordenstrom J, Arner P: Demonstration of an in vivo functional β3-adrenoceptor in man. J Clin Invest. 1995, 95: 2239-2245.PubMedPubMedCentralCrossRef
11.
go back to reference Arner P, Hoffstedt J: Adrenoceptor genes in human obesity. J Intern Med. 1999, 245: 667-672. 10.1046/j.1365-2796.1999.00495.x.PubMedCrossRef Arner P, Hoffstedt J: Adrenoceptor genes in human obesity. J Intern Med. 1999, 245: 667-672. 10.1046/j.1365-2796.1999.00495.x.PubMedCrossRef
12.
go back to reference Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfeld L, Arner P: Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest. 1997, 100: 3005-3013.PubMedPubMedCentralCrossRef Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfeld L, Arner P: Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest. 1997, 100: 3005-3013.PubMedPubMedCentralCrossRef
13.
go back to reference Kortner B, Wolf A, Wendt D, Beisiegel U, Evans D: Lack of association between a human β-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. Int J Obes Relat Metab Disord. 1999, 23: 1099-1100. 10.1038/sj/ijo/0801063.PubMedCrossRef Kortner B, Wolf A, Wendt D, Beisiegel U, Evans D: Lack of association between a human β-2 adrenoceptor gene polymorphism (gln27glu) and morbid obesity. Int J Obes Relat Metab Disord. 1999, 23: 1099-1100. 10.1038/sj/ijo/0801063.PubMedCrossRef
14.
go back to reference Sakane N, Yoshida T, Umekawa T, Kogure A, Kondo M: Beta2-adrenoceptor gene polymorphism and obesity [letter]. Lancet. 1999, 353: 1976-PubMedCrossRef Sakane N, Yoshida T, Umekawa T, Kogure A, Kondo M: Beta2-adrenoceptor gene polymorphism and obesity [letter]. Lancet. 1999, 353: 1976-PubMedCrossRef
15.
go back to reference Meirhaeghe A, Helbecque N, Cottel D, Amouyel P: Beta2-adrenoceptor gene polymorphism, body weight, and physical activity [letter]. Lancet. 1999, 353: 896-10.1016/S0140-6736(99)00251-2.PubMedCrossRef Meirhaeghe A, Helbecque N, Cottel D, Amouyel P: Beta2-adrenoceptor gene polymorphism, body weight, and physical activity [letter]. Lancet. 1999, 353: 896-10.1016/S0140-6736(99)00251-2.PubMedCrossRef
16.
go back to reference Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N: A mutation in the β3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun. 1995, 215: 555-560. 10.1006/bbrc.1995.2500.PubMedCrossRef Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N: A mutation in the β3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun. 1995, 215: 555-560. 10.1006/bbrc.1995.2500.PubMedCrossRef
17.
go back to reference Yoshioka K, Yoshida T, Sakane N, Umekawa T, Takahashi T, Sakai Y, Kondo M: Association of Trp64Arg mutation of the beta 3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia. 1996, 39: 1410-1411.PubMed Yoshioka K, Yoshida T, Sakane N, Umekawa T, Takahashi T, Sakai Y, Kondo M: Association of Trp64Arg mutation of the beta 3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia. 1996, 39: 1410-1411.PubMed
18.
go back to reference Gagnon J, Mauriege P, Roy S, Sjostrom D, Chagnon YC, Dionne FT, Oppert JM, Perusse L, Sjostrom L, Bouchard C: The Trp64Arg mutation of the beta 3 adrenergic receptor gene has no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohorts. J Clin Invest. 1996, 98: 2086-2093.PubMedPubMedCentralCrossRef Gagnon J, Mauriege P, Roy S, Sjostrom D, Chagnon YC, Dionne FT, Oppert JM, Perusse L, Sjostrom L, Bouchard C: The Trp64Arg mutation of the beta 3 adrenergic receptor gene has no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohorts. J Clin Invest. 1996, 98: 2086-2093.PubMedPubMedCentralCrossRef
19.
go back to reference SAS Institute:. SAS/STAT User's guide, ver 6, 4th ed. Cary, NC: SAS Institute Inc;. 1990 SAS Institute:. SAS/STAT User's guide, ver 6, 4th ed. Cary, NC: SAS Institute Inc;. 1990
20.
go back to reference Sato R: The role of beta2-adrenoceptor gene polymorphism in asthma. Hokkaido J Med Sci. 2000, 75: 81-94.PubMed Sato R: The role of beta2-adrenoceptor gene polymorphism in asthma. Hokkaido J Med Sci. 2000, 75: 81-94.PubMed
21.
go back to reference Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T: Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia. 1996, 39: 349-352. 10.1007/s001250050452.PubMedCrossRef Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T: Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia. 1996, 39: 349-352. 10.1007/s001250050452.PubMedCrossRef
22.
go back to reference Stata Corp:. Stata Statistical Software, release 6. College Station, TX: Stata Corporation;. 1999 Stata Corp:. Stata Statistical Software, release 6. College Station, TX: Stata Corporation;. 1999
23.
go back to reference Hamajima N, Yuasa H, Matsuo K, Kurobe Y: Detection of gene-environment interaction by case-only studies. Jpn J Clin Oncol. 1999, 29: 490-493. 10.1093/jjco/29.10.490.PubMedCrossRef Hamajima N, Yuasa H, Matsuo K, Kurobe Y: Detection of gene-environment interaction by case-only studies. Jpn J Clin Oncol. 1999, 29: 490-493. 10.1093/jjco/29.10.490.PubMedCrossRef
24.
go back to reference Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S: Epidemiological features of first-visit outpatients in Japan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol. 1997, 50: 69-77. 10.1016/S0895-4356(96)00297-1.PubMedCrossRef Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S: Epidemiological features of first-visit outpatients in Japan: comparison with general population and variation by sex, age, and season. J Clin Epidemiol. 1997, 50: 69-77. 10.1016/S0895-4356(96)00297-1.PubMedCrossRef
25.
go back to reference Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K: Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia. 1996, 42: 98-101. 10.1007/s001250051120.CrossRef Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K: Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia. 1996, 42: 98-101. 10.1007/s001250051120.CrossRef
26.
go back to reference Kyogoku S, Hirohata T, Takeshita S, Hirota Y, Shigematsu T: Anthropometric indicators of breast cancer risk in Japanese women in Fukuoka. Jpn J Cancer Res. 1990, 81: 731-737.PubMedCrossRef Kyogoku S, Hirohata T, Takeshita S, Hirota Y, Shigematsu T: Anthropometric indicators of breast cancer risk in Japanese women in Fukuoka. Jpn J Cancer Res. 1990, 81: 731-737.PubMedCrossRef
27.
go back to reference Arner P: Adrenergic receptor function in fat cells. Am J Clin Nutr. 1989, 55(suppl): S228-S236. Arner P: Adrenergic receptor function in fat cells. Am J Clin Nutr. 1989, 55(suppl): S228-S236.
28.
go back to reference Lafontan M, Barbe P, Galitzky J, Tavernier G, Langin D, Carpene C, Bousquet-Melou A, Berlan M: Adrenergic regulation of adipocyte metabolism. Hum Reprod. 1997, 12(suppl 1): 16-20. Lafontan M, Barbe P, Galitzky J, Tavernier G, Langin D, Carpene C, Bousquet-Melou A, Berlan M: Adrenergic regulation of adipocyte metabolism. Hum Reprod. 1997, 12(suppl 1): 16-20.
Metadata
Title
Possible association of β2- and β3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer
Authors
Xin-En Huang
Nobuyuki Hamajima
Toshiko Saito
Keitaro Matsuo
Mitsuhiro Mizutani
Hiroji Iwata
Takuji Iwase
Shigeto Miura
Tsutomu Mizuno
Shinkan Tokudome
Kazuo Tajima
Publication date
01-08-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2001
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr304

Other articles of this Issue 4/2001

Breast Cancer Research 4/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine